vs
SCANSOURCE, INC.（SCSC）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是SCANSOURCE, INC.的2.0倍（$1.5B vs $766.5M），Steris净利率更高（12.9% vs 2.2%，领先10.7%），Steris同比增速更快（9.2% vs 2.5%），Steris自由现金流更多（$199.5M vs $28.9M），过去两年Steris的营收复合增速更高（15.8% vs 0.9%）
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
SCSC vs STE — 直观对比
营收规模更大
STE
是对方的2.0倍
$766.5M
营收增速更快
STE
高出6.6%
2.5%
净利率更高
STE
高出10.7%
2.2%
自由现金流更多
STE
多$170.6M
$28.9M
两年增速更快
STE
近两年复合增速
0.9%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $766.5M | $1.5B |
| 净利润 | $16.5M | $192.9M |
| 毛利率 | 13.4% | 43.8% |
| 营业利润率 | 2.3% | 18.3% |
| 净利率 | 2.2% | 12.9% |
| 营收同比 | 2.5% | 9.2% |
| 净利润同比 | -3.3% | 11.2% |
| 每股收益（稀释后） | $0.75 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCSCSTE
| Q4 25 | $766.5M | $1.5B | ||
| Q3 25 | $739.6M | $1.5B | ||
| Q2 25 | $812.9M | $1.4B | ||
| Q1 25 | $704.8M | $1.5B | ||
| Q4 24 | $747.5M | $1.4B | ||
| Q3 24 | $775.6M | $1.3B | ||
| Q2 24 | $746.1M | $1.3B | ||
| Q1 24 | $752.6M | $1.1B |
净利润SCSCSTE
| Q4 25 | $16.5M | $192.9M | ||
| Q3 25 | $19.9M | $191.9M | ||
| Q2 25 | $20.1M | $177.4M | ||
| Q1 25 | $17.4M | $145.7M | ||
| Q4 24 | $17.1M | $173.5M | ||
| Q3 24 | $17.0M | $150.0M | ||
| Q2 24 | $16.1M | $145.4M | ||
| Q1 24 | $12.8M | $-1.4M |
毛利率SCSCSTE
| Q4 25 | 13.4% | 43.8% | ||
| Q3 25 | 14.5% | 44.2% | ||
| Q2 25 | 12.9% | 45.1% | ||
| Q1 25 | 14.2% | 43.3% | ||
| Q4 24 | 13.6% | 44.5% | ||
| Q3 24 | 13.1% | 43.6% | ||
| Q2 24 | 13.0% | 44.7% | ||
| Q1 24 | 12.6% | 40.2% |
营业利润率SCSCSTE
| Q4 25 | 2.3% | 18.3% | ||
| Q3 25 | 3.5% | 18.2% | ||
| Q2 25 | 3.3% | 17.7% | ||
| Q1 25 | 3.2% | 14.6% | ||
| Q4 24 | 2.5% | 17.9% | ||
| Q3 24 | 2.3% | 16.5% | ||
| Q2 24 | 2.9% | 14.5% | ||
| Q1 24 | 2.3% | 22.0% |
净利率SCSCSTE
| Q4 25 | 2.2% | 12.9% | ||
| Q3 25 | 2.7% | 13.1% | ||
| Q2 25 | 2.5% | 12.8% | ||
| Q1 25 | 2.5% | 9.8% | ||
| Q4 24 | 2.3% | 12.7% | ||
| Q3 24 | 2.2% | 11.3% | ||
| Q2 24 | 2.2% | 11.4% | ||
| Q1 24 | 1.7% | -0.1% |
每股收益（稀释后）SCSCSTE
| Q4 25 | $0.75 | $1.96 | ||
| Q3 25 | $0.89 | $1.94 | ||
| Q2 25 | $0.87 | $1.79 | ||
| Q1 25 | $0.74 | $1.48 | ||
| Q4 24 | $0.70 | $1.75 | ||
| Q3 24 | $0.69 | $1.51 | ||
| Q2 24 | $0.66 | $1.46 | ||
| Q1 24 | $0.50 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.5M | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $910.9M | $7.2B |
| 总资产 | $1.7B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资SCSCSTE
| Q4 25 | $83.5M | $423.7M | ||
| Q3 25 | $124.9M | $319.2M | ||
| Q2 25 | $126.2M | $279.7M | ||
| Q1 25 | $146.3M | $171.7M | ||
| Q4 24 | $110.5M | $155.2M | ||
| Q3 24 | $145.0M | $172.2M | ||
| Q2 24 | $185.5M | $198.3M | ||
| Q1 24 | $159.1M | $207.0M |
总债务SCSCSTE
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益SCSCSTE
| Q4 25 | $910.9M | $7.2B | ||
| Q3 25 | $914.0M | $7.0B | ||
| Q2 25 | $906.4M | $7.0B | ||
| Q1 25 | $901.7M | $6.6B | ||
| Q4 24 | $900.7M | $6.4B | ||
| Q3 24 | $920.9M | $6.6B | ||
| Q2 24 | $924.3M | $6.4B | ||
| Q1 24 | $944.1M | $6.3B |
总资产SCSCSTE
| Q4 25 | $1.7B | $10.6B | ||
| Q3 25 | $1.7B | $10.4B | ||
| Q2 25 | $1.8B | $10.4B | ||
| Q1 25 | $1.7B | $10.1B | ||
| Q4 24 | $1.7B | $10.0B | ||
| Q3 24 | $1.8B | $10.2B | ||
| Q2 24 | $1.8B | $10.1B | ||
| Q1 24 | $1.8B | $11.1B |
负债/权益比SCSCSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.8M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $28.9M | $199.5M |
| 自由现金流率自由现金流/营收 | 3.8% | 13.3% |
| 资本支出强度资本支出/营收 | 0.3% | 6.6% |
| 现金转化率经营现金流/净利润 | 1.87× | 1.55× |
| 过去12个月自由现金流最近4个季度 | — | $917.1M |
8季度趋势，按日历期对齐
经营现金流SCSCSTE
| Q4 25 | $30.8M | $298.2M | ||
| Q3 25 | $23.2M | $287.8M | ||
| Q2 25 | — | $420.0M | ||
| Q1 25 | $66.1M | $260.8M | ||
| Q4 24 | $-6.2M | $332.8M | ||
| Q3 24 | $44.8M | $250.7M | ||
| Q2 24 | — | $303.7M | ||
| Q1 24 | $160.2M | $254.8M |
自由现金流SCSCSTE
| Q4 25 | $28.9M | $199.5M | ||
| Q3 25 | $20.8M | $201.3M | ||
| Q2 25 | — | $326.4M | ||
| Q1 25 | $64.6M | $189.9M | ||
| Q4 24 | $-8.2M | $243.6M | ||
| Q3 24 | $42.5M | $148.8M | ||
| Q2 24 | — | $195.7M | ||
| Q1 24 | $157.7M | $163.3M |
自由现金流率SCSCSTE
| Q4 25 | 3.8% | 13.3% | ||
| Q3 25 | 2.8% | 13.8% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | 9.2% | 12.8% | ||
| Q4 24 | -1.1% | 17.8% | ||
| Q3 24 | 5.5% | 11.2% | ||
| Q2 24 | — | 15.3% | ||
| Q1 24 | 21.0% | 14.6% |
资本支出强度SCSCSTE
| Q4 25 | 0.3% | 6.6% | ||
| Q3 25 | 0.3% | 5.9% | ||
| Q2 25 | 0.3% | 6.7% | ||
| Q1 25 | 0.2% | 4.8% | ||
| Q4 24 | 0.3% | 6.5% | ||
| Q3 24 | 0.3% | 7.7% | ||
| Q2 24 | 0.2% | 8.4% | ||
| Q1 24 | 0.3% | 8.2% |
现金转化率SCSCSTE
| Q4 25 | 1.87× | 1.55× | ||
| Q3 25 | 1.17× | 1.50× | ||
| Q2 25 | — | 2.37× | ||
| Q1 25 | 3.79× | 1.79× | ||
| Q4 24 | -0.36× | 1.92× | ||
| Q3 24 | 2.64× | 1.67× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | 12.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
